1. Home
  2. DBVT vs SOL Comparison

DBVT vs SOL Comparison

Compare DBVT & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • SOL
  • Stock Information
  • Founded
  • DBVT 2002
  • SOL 2005
  • Country
  • DBVT France
  • SOL United States
  • Employees
  • DBVT N/A
  • SOL N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • SOL Semiconductors
  • Sector
  • DBVT Health Care
  • SOL Technology
  • Exchange
  • DBVT Nasdaq
  • SOL Nasdaq
  • Market Cap
  • DBVT 102.0M
  • SOL 84.6M
  • IPO Year
  • DBVT N/A
  • SOL 2008
  • Fundamental
  • Price
  • DBVT $9.84
  • SOL $1.50
  • Analyst Decision
  • DBVT Strong Buy
  • SOL Buy
  • Analyst Count
  • DBVT 3
  • SOL 3
  • Target Price
  • DBVT $13.67
  • SOL $3.50
  • AVG Volume (30 Days)
  • DBVT 81.5K
  • SOL 160.9K
  • Earning Date
  • DBVT 04-30-2025
  • SOL 05-22-2025
  • Dividend Yield
  • DBVT N/A
  • SOL N/A
  • EPS Growth
  • DBVT N/A
  • SOL N/A
  • EPS
  • DBVT N/A
  • SOL N/A
  • Revenue
  • DBVT $3,497,000.00
  • SOL $92,067,000.00
  • Revenue This Year
  • DBVT $1,700.53
  • SOL N/A
  • Revenue Next Year
  • DBVT $535.67
  • SOL $45.37
  • P/E Ratio
  • DBVT N/A
  • SOL N/A
  • Revenue Growth
  • DBVT N/A
  • SOL N/A
  • 52 Week Low
  • DBVT $0.44
  • SOL $1.04
  • 52 Week High
  • DBVT $9.90
  • SOL $3.00
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 68.41
  • SOL 57.84
  • Support Level
  • DBVT $8.59
  • SOL $1.25
  • Resistance Level
  • DBVT $9.90
  • SOL $1.40
  • Average True Range (ATR)
  • DBVT 0.77
  • SOL 0.07
  • MACD
  • DBVT -0.02
  • SOL 0.03
  • Stochastic Oscillator
  • DBVT 91.04
  • SOL 91.94

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

About SOL Emeren Group Ltd each representing 10 shares

Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.

Share on Social Networks: